
Francesca Viazzi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9201617/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	High heart rate amplifies the risk of cardiovascular mortality associated with elevated uric acid. European Journal of Preventive Cardiology, 2022, 29, 1501-1509.	0.8	9
2	Association of uric acid with kidney function and albuminuria: the Uric Acid Right for heArt Health (URRAH) Project. Journal of Nephrology, 2022, 35, 211-221.	0.9	34
3	Identification of a plausible serum uric acid cut-off value as prognostic marker of stroke: the Uric Acid Right for Heart Health (URRAH) study. Journal of Human Hypertension, 2022, 36, 976-982.	1.0	20
4	Myostatin: Basic biology to clinical application. Advances in Clinical Chemistry, 2022, 106, 181-234.	1.8	21
5	Serum uric acid levels threshold for mortality in diabetic individuals: The URic acid Right for heArt Health (URRAH) project. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 1245-1252.	1.1	15
6	Uric acid lowering for slowing CKD progression after the CKD-FIX trial: a solved question or still a dilemma?. CKJ: Clinical Kidney Journal, 2022, 15, 1666-1674.	1.4	5
7	The association of uric acid with mortality modifies at old age: data from the uric acid right for heart health (URRAH) study. Journal of Hypertension, 2022, 40, 704-711.	0.3	12
8	Impact of eGFR rate on 1-year all-cause mortality in patients with stable coronary artery disease. European Journal of Internal Medicine, 2022, 101, 98-105.	1.0	2
9	MO330: AKI and Renal Parenchyma Attenuation in Hospitalized Patients With COVID-19. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0
10	FC027: Uric Acid Stimulates Cytoskeleton Pathways in Vascular Smooth Muscle Cells Through F-ACTIN Polymerization and Atrogin, Îʿsma and SM22 up Regulation. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0
11	Changes of Acute Kidney Injury Epidemiology during the COVID-19 Pandemic: A Retrospective Cohort Study. Journal of Clinical Medicine, 2022, 11, 3349.	1.0	10
12	Outcomes on safety and efficacy of left atrial appendage occlusion in end stage renal disease patients undergoing dialysis. Journal of Nephrology, 2021, 34, 63-73.	0.9	38
13	Duration of antibiotic therapy in pyelonephritis: when shorter is better. Internal and Emergency Medicine, 2021, 16, 259-261.	1.0	2
14	Kidney disease and all-cause mortality in patients with COVID-19 hospitalized in Genoa, Northern Italy. Journal of Nephrology, 2021, 34, 173-183.	0.9	52
15	Treating Hyperuricemia: The Last Word Hasn't Been Said Yet. Journal of Clinical Medicine, 2021, 10, 819.	1.0	13
16	Central lineâ€associated bloodstream infections in hemodialysis patients in the <scp>COVID</scp> â€19 era. Hemodialysis International, 2021, 25, 275-278.	0.4	1
17	The importance of including uric acid in the definition of metabolic syndrome when assessing the mortality risk. Clinical Research in Cardiology, 2021, 110, 1073-1082.	1.5	31
18	Effects of Late Conversion from Twice-Daily to Once-Daily Slow Release Tacrolimus on the Insulin Resistance Indexes in Kidney Transplant Patients. Transplantology, 2021, 2, 49-56.	0.3	0

#	Article	IF	CITATIONS
19	The URRAH study. Panminerva Medica, 2021, 63, .	0.2	16
20	Effects of Different Dialysis Strategies on Inflammatory Cytokine Profile in Maintenance Hemodialysis Patients with COVID-19: A Randomized Trial. Journal of Clinical Medicine, 2021, 10, 1383.	1.0	6
21	SGLT2is and Renal Protection: From Biological Mechanisms to Real-World Clinical Benefits. International Journal of Molecular Sciences, 2021, 22, 4441.	1.8	27
22	MO905EFFECTS OF DIFFERENT DIALYSIS TECHNIQUES ON INFLAMMATION IN MAINTENANCE HEMODIALYSIS PATIENTS WITH COVID-19: A RANDOMIZED STUDY. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0
23	Relationship between endothelin and nitric oxide pathways in the onset and maintenance of hypertension in children and adolescents. Pediatric Nephrology, 2021, , 1.	0.9	13
24	Relationship between uric acid and kidney function in adults at risk for tumor lysis syndrome. Leukemia and Lymphoma, 2021, 62, 3067-3069.	0.6	0
25	How to Overcome Anabolic Resistance in Dialysis-Treated Patients?. Frontiers in Nutrition, 2021, 8, 701386.	1.6	5
26	Myostatin/Activin-A Signaling in the Vessel Wall and Vascular Calcification. Cells, 2021, 10, 2070.	1.8	6
27	Serum Uric Acid and Kidney Disease Measures Independently Predict Cardiovascular and Total Mortality: The Uric Acid Right for Heart Health (URRAH) Project. Frontiers in Cardiovascular Medicine, 2021, 8, 713652.	1.1	18
28	Serum uric acid, predicts heart failure in a large Italian cohort: search for a cut-off value the URic acid Right for heArt Health study. Journal of Hypertension, 2021, 39, 62-69.	0.3	49
29	Relationships between diuretic-related hyperuricemia and cardiovascular events: data from the URic acid Right for heArt Health study. Journal of Hypertension, 2021, 39, 333-340.	0.3	46
30	Low Protein Diets and Plant-Based Low Protein Diets: Do They Meet Protein Requirements of Patients with Chronic Kidney Disease?. Nutrients, 2021, 13, 83.	1.7	27
31	Hyperkalemia-induced acute flaccid paralysis: a case report. Giornale Italiano Di Nefrologia: Organo Ufficiale Della Società Italiana Di Nefrologia, 2021, 38, .	0.3	0
32	Two-Day ABPM-Derived Indices and Mortality in Hemodialysis Patients. American Journal of Hypertension, 2020, 33, 165-174.	1.0	1
33	Blood pressure phenotype: an evolving picture. Internal and Emergency Medicine, 2020, 15, 19-20.	1.0	1
34	Uric acid in CKD: has the jury come to the verdict?. Journal of Nephrology, 2020, 33, 715-724.	0.9	44
35	Effects of dual inhibition of renin–angiotensin–aldosterone system on cardiovascular and renal outcomes: balancing the risks and the benefits. Internal and Emergency Medicine, 2020, 15, 373-379.	1.0	3
36	Identification of the Uric Acid Thresholds Predicting an Increased Total and Cardiovascular Mortality Over 20 Years. Hypertension, 2020, 75, 302-308.	1.3	177

#	Article	IF	CITATIONS
37	Serum uric acid and fatal myocardial infarction: detection of prognostic cut-off values: The URRAH (Uric Acid Right for Heart Health) study. Journal of Hypertension, 2020, 38, 412-419.	0.3	70
38	Long-term blood pressure variability, incidence of hypertension and changes in renal function in type 2 diabetes. Journal of Hypertension, 2020, 38, 2279-2286.	0.3	11
39	Ten-Year Efficacy and Safety of Once-Daily Tacrolimus in Kidney Transplant: A Prospective Cohort Study. Transplantation Proceedings, 2020, 52, 3112-3117.	0.3	3
40	Blood pressure reduction and RAAS inhibition in diabetic kidney disease: therapeutic potentials and limitations. Journal of Nephrology, 2020, 33, 949-963.	0.9	31
41	New Treatment Options for Hyperkalemia in Patients with Chronic Kidney Disease. Journal of Clinical Medicine, 2020, 9, 2337.	1.0	13
42	Increased serum uric acid levels are associated to renal arteriolopathy and predict poor outcome in IgA nephropathy. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 2343-2350.	1.1	20
43	P0010INCREASED SERUM URIC ACID LEVELS ARE ASSOCIATED TO RENAL ARTERIOLOPATHY AND PREDICT POOR OUTCOME IN IGA NEPHROPATHY. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
44	MO040LONG-TERM FOLLOW-UP OF IGA NEPHROPATHY PATIENTS AT HIGH RISK OF PROGRESSION ACCORDING TO THE THERAPEUTIC APPROACH EMPLOYED: A MULTICENTER RETROSPECTIVE STUDY OF 947 PATIENTS. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
45	P0276SERUM C3 LEVELS AND THE PROGNOSIS OF ANCA-ASSOCIATED VASCULITIS: A SINGLE-CENTER RETROSPECTIVE STUDY. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
46	Long-term blood pressure behavior and progression to end-stage renal disease in patients with immunoglobulin A nephropathy: a single-center observational study in Italy. Journal of Hypertension, 2020, 38, 925-935.	0.3	7
47	Management of <scp>COVID</scp> â€19 in hemodialysis patients: The Genoa experience. Hemodialysis International, 2020, 24, 423-427.	0.4	15
48	Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. New England Journal of Medicine, 2020, 382, 2168-2169.	13.9	17
49	Hyperuricemia and Risk of Cardiovascular Outcomes: The Experience of the URRAH (Uric Acid Right for) Tj ETQq1	1 0,7843 1.0	14 rgBT /Ov
50	Fructose and Uric Acid: Major Mediators of Cardiovascular Disease Risk Starting at Pediatric Age. International Journal of Molecular Sciences, 2020, 21, 4479.	1.8	31
51	Effect of Bempedoic Acid on Serum Uric Acid and Related Outcomes: A Systematic Review and Meta-analysis of the available Phase 2 and Phase 3 Clinical Studies. Drug Safety, 2020, 43, 727-736.	1.4	37
52	Atherogenic dyslipidemia and diabetic nephropathy. Journal of Nephrology, 2020, 33, 1001-1008.	0.9	36
53	Enhanced myostatin expression and signalling promote tubulointerstitial inflammation in diabetic nephropathy. Scientific Reports, 2020, 10, 6343.	1.6	14
54	Nutritional Challenges in Pregnant Women with Renal Diseases: Relevance to Fetal Outcomes. Nutrients, 2020, 12, 873.	1.7	6

#	Article	IF	CITATIONS
55	Cellular Senescence Is Associated with Faster Progression of Focal Segmental Glomerulosclerosis. American Journal of Nephrology, 2020, 51, 950-958.	1.4	7
56	Renal Parenchymal Disease. Updates in Hypertension and Cardiovascular Protection, 2020, , 1-19.	0.1	0
57	Antihypertensive Treatment in Diabetic Kidney Disease: The Need for a Patient-Centered Approach. Medicina (Lithuania), 2019, 55, 382.	0.8	5
58	FO052MYOSTATIN PROMOTES TUBULAR INFLAMMATION IN DIABETIC NEPHROPATHY. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
59	Impact of CVOTs in primary and secondary prevention of kidney disease. Diabetes Research and Clinical Practice, 2019, 157, 107907.	1.1	5
60	We are far from achieving blood pressure goals in diabetes: Do we really want to do it?. Journal of Clinical Hypertension, 2019, 21, 1664-1665.	1.0	0
61	The Organ Handling of Soluble Klotho in Humans. Kidney and Blood Pressure Research, 2019, 44, 715-726.	0.9	11
62	GLP-1 Receptor Agonists and Kidney Protection. Medicina (Lithuania), 2019, 55, 233.	0.8	75
63	Baseline hsâ€CRP predicts hypertension remission in metabolic syndrome. European Journal of Clinical Investigation, 2019, 49, e13128.	1.7	24
64	Causes and impact on survival of underuse of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in heart failure. Internal and Emergency Medicine, 2019, 14, 1083-1090.	1.0	5
65	Endothelin-1/nitric oxide balance and HOMA index in children with excess weight and hypertension: a pathophysiological model of hypertension. Hypertension Research, 2019, 42, 1192-1199.	1.5	8
66	Overall Quality of Care Predicts the Variability of Key Risk Factors for Complications in Type 2 Diabetes: An Observational, Longitudinal Retrospective Study. Diabetes Care, 2019, 42, 514-519.	4.3	28
67	Long-term blood pressure variability and development of chronic kidney disease in type 2 diabetes. Journal of Hypertension, 2019, 37, 805-813.	0.3	23
68	Natural history and risk factors for diabetic kidney disease in patients with T2D: lessons from the AMD-annals. Journal of Nephrology, 2019, 32, 517-525.	0.9	30
69	Uric acid and angiotensin II additively promote inflammation and oxidative stress in human proximal tubule cells by activation of tollâ€like receptor 4. Journal of Cellular Physiology, 2019, 234, 10868-10876.	2.0	51
70	Changes in albuminuria and renal outcome in patients with type 2 diabetes and hypertension. Journal of Hypertension, 2018, 36, 1719-1728.	0.3	10
71	Apparent Treatment Resistant Hypertension, Blood Pressure Control and the Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes. Kidney and Blood Pressure Research, 2018, 43, 422-438.	0.9	19
72	FP029INDOXYL SULFATE INDUCES FIBROSIS AND INFLAMMATION BY UPREGULATING HEAT SHOCK PROTEIN 90 (HSP 90) IN RENAL FIBROBLASTS. Nephrology Dialysis Transplantation, 2018, 33, i58-i58.	0.4	0

#	Article	IF	CITATIONS
73	Association of kidney disease measures with risk of renal function worsening in patients with type 1 diabetes. BMC Nephrology, 2018, 19, 347.	0.8	2
74	Antihypertensive treatment and renal protection: Is there a J urve relationship?. Journal of Clinical Hypertension, 2018, 20, 1560-1574.	1.0	17
75	Hypertensive Versus HIV-infected Patients: Who Has the Greatest Target Organ Damage? Comparison of Carotid Plaque Prevalence, Intima Media Thickness and Renal Resistive Index in the Two Groups of Patients. Current Hypertension Reviews, 2018, 14, 48-55.	0.5	2
76	Five-Year Predictors of Insulin Initiation in People with Type 2 Diabetes under Real-Life Conditions. Journal of Diabetes Research, 2018, 2018, 1-10.	1.0	13
77	Diabetic kidney disease in the elderly: prevalence and clinical correlates. BMC Geriatrics, 2018, 18, 38.	1.1	47
78	Normoalbuminuric kidney impairment in patients with T1DM: insights from annals initiative. Diabetology and Metabolic Syndrome, 2018, 10, 60.	1.2	15
79	Peripheral artery disease and blood pressure profile abnormalities in hemodialysis patients. Journal of Nephrology, 2017, 30, 427-433.	0.9	8
80	Variability in <scp>HbA1c</scp> , blood pressure, lipid parameters and serum uric acid, and risk of development of chronic kidney disease in type 2 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 1570-1578.	2.2	70
81	Tollâ€like receptor 4 signalling mediates inflammation in skeletal muscle of patients with chronic kidney disease. Journal of Cachexia, Sarcopenia and Muscle, 2017, 8, 131-144.	2.9	62
82	Epidemiology of diabetic kidney disease in adult patients with type 1 diabetes in Italy: The AMDâ€Annals initiative. Diabetes/Metabolism Research and Reviews, 2017, 33, e2873.	1.7	26
83	Longitudinal Association Between Serum Uric Acid and Arterial Stiffness. Hypertension, 2017, 69, 228-235.	1.3	59
84	Resistant Hypertension, Timeâ€Updated Blood Pressure Values and Renal Outcome in Type 2 Diabetes Mellitus. Journal of the American Heart Association, 2017, 6, .	1.6	21
85	Toll-like receptor-4 signaling mediates inflammation and tissue injury in diabetic nephropathy. Journal of Nephrology, 2017, 30, 719-727.	0.9	66
86	Kidney disease measures are associated with the burden of coronary atherosclerosis, independently of diabetes. Acta Diabetologica, 2017, 54, 1065-1068.	1.2	3
87	SP264THE KIDNEY IS THE MAJOR SITE FOR THE REGULATION OF SOLUBLE KLOTHO IN HUMANS. Nephrology Dialysis Transplantation, 2017, 32, iii195-iii195.	0.4	0
88	Predictors of chronic kidney disease in type 1 diabetes: a longitudinal study from the AMD Annals initiative. Scientific Reports, 2017, 7, 3313.	1.6	23
89	Interorgan handling of fibroblast growth factor-23 in humans. American Journal of Physiology - Renal Physiology, 2017, 312, F254-F258.	1.3	4
90	Association of kidney disease measures with risk of renal function worsening in patients with hypertension and type 2 diabetes. Journal of Diabetes and Its Complications, 2017, 31, 419-426.	1.2	22

#	Article	IF	CITATIONS
91	Metabolic syndrome, serum uric acid and renal risk in patients with T2D. PLoS ONE, 2017, 12, e0176058.	1.1	25
92	Antihyperglycemic treatment in patients with type 2 diabetes in Italy: the impact of age and kidney function. Oncotarget, 2017, 8, 62039-62048.	0.8	7
93	Albuminuria. Journal of Hypertension, 2016, 34, 399-401.	0.3	4
94	Can we predict outcome by noninvasive assessment of renal haemodynamics in hypertension? The role of renal resistive index. Journal of Hypertension, 2016, 34, 1047-1049.	0.3	3
95	Changes in albuminuria and cardiovascular risk under antihypertensive treatment. Journal of Hypertension, 2016, 34, 1689-1697.	0.3	26
96	Blood pressure status and the incidence of diabetic kidney disease in patients with hypertension and type 2 diabetes. Journal of Hypertension, 2016, 34, 2090-2098.	0.3	28
97	Renin–angiotensin–aldosterone system blockade in chronic kidney disease: current strategies and a look ahead. Internal and Emergency Medicine, 2016, 11, 627-635.	1.0	28
98	Increased Serum Uric Acid Levels Blunt the Antihypertensive Efficacy of Lifestyle Modifications in Children at Cardiovascular Risk. Hypertension, 2016, 67, 934-940.	1.3	36
99	Novelty in hypertension in children and adolescents: focus on hypertension during the first year of life, use and interpretation of ambulatory blood pressure monitoring, role of physical activity in prevention and treatment, simple carbohydrates and uric acid as risk factors. Italian Journal of Pediatrics, 2016, 42, 69.	1.0	15
100	Plasma Triglycerides and HDL-C Levels Predict the Development of Diabetic Kidney Disease in Subjects With Type 2 Diabetes: The AMD Annals Initiative. Diabetes Care, 2016, 39, 2278-2287.	4.3	93
101	Microalbuminuria in primary hypertension: a guide to optimal patient management?. Journal of Nephrology, 2016, 29, 747-753.	0.9	18
102	Predictors of chronic kidney disease in type 2 diabetes. Medicine (United States), 2016, 95, e4007.	0.4	48
103	Prevalent cardiac, renal and cardiorenal damage in patients with advanced abdominal aortic aneurysms. Internal and Emergency Medicine, 2016, 11, 205-212.	1.0	10
104	Metabolic syndrome is associated with left ventricular dilatation in primary hypertension. Journal of Human Hypertension, 2016, 30, 158-163.	1.0	11
105	Chronic kidney disease as a predictor of clinical risk in the elderly. Journal of Geriatric Cardiology, 2016, 13, 199-201.	0.2	2
106	Sugar, fructose, uric acid and hypertension in children and adolescents. Italian Journal of Pediatrics, 2015, 41, .	1.0	2
107	Left ventricular dilatation and subclinical renal damage in primary hypertension. Journal of Hypertension, 2015, 33, 605-611.	0.3	10
108	Trend of eGFR in an Italian cohort of mother-to-child HIV-infected patients exposed to tenofovir for at least 2Âyears. European Journal of Pediatrics, 2015, 174, 843-846.	1.3	1

#	Article	IF	CITATIONS
109	Achievement of therapeutic targets in patients with diabetes and chronic kidney disease: insights from the Associazione Medici Diabetologi Annals initiative. Nephrology Dialysis Transplantation, 2015, 30, 1526-1533.	0.4	39
110	Insulin sensitivity of muscle protein metabolism is altered in patients with chronic kidney disease and metabolic acidosis. Kidney International, 2015, 88, 1419-1426.	2.6	48
111	Serum Uric Acid and Risk of CKD in Type 2 Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1921-1929.	2.2	136
112	Increased urine semaphorin-3A is associated with renal damage in hypertensive patients with chronic kidney disease: a nested case–control study. Journal of Nephrology, 2015, 28, 315-320.	0.9	9
113	Uric Acid Promotes Apoptosis in Human Proximal Tubule Cells by Oxidative Stress and the Activation of NADPH Oxidase NOX 4. PLoS ONE, 2014, 9, e115210.	1.1	101
114	Early Renal Abnormalities as an Indicator of Cardiovascular Risk in Type 2 Diabetes. High Blood Pressure and Cardiovascular Prevention, 2014, 21, 257-260.	1.0	4
115	Enhanced glomerular Toll-like receptor 4 expression and signaling in patients with type 2 diabetic nephropathy and microalbuminuria. Kidney International, 2014, 86, 1229-1243.	2.6	77
116	Vitamin D modulates the association of circulating insulin-like growth factor-1 with carotid artery intima-media thickness. Atherosclerosis, 2014, 236, 418-425.	0.4	17
117	Kidney dysfunction and related cardiovascular risk factors among patients with type 2 diabetes. Nephrology Dialysis Transplantation, 2014, 29, 657-662.	0.4	49
118	Inferior vena cava parameters predict reâ€admission in ischaemic heart failure. European Journal of Clinical Investigation, 2014, 44, 341-349.	1.7	27
119	Ultrasound Doppler renal resistive index. Journal of Hypertension, 2014, 32, 149-153.	0.3	117
120	Serum uric acid and its relationship with metabolic syndrome and cardiovascular risk profile in patients with hypertension: Insights from the I-DEMAND study. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 921-927.	1.1	38
121	Hyperuricemia and Renal Risk. High Blood Pressure and Cardiovascular Prevention, 2014, 21, 189-194.	1.0	15
122	Blood pressure, albuminuria and renal dysfunction: the 'chicken or egg' dilemma. Nephrology Dialysis Transplantation, 2014, 29, 1453-1455.	0.4	18
123	Looking at the kidney to predict global outcome in the elderly. Internal and Emergency Medicine, 2014, 9, 711-713.	1.0	Ο
124	Blood pressure variability and multiple organ damage in primary hypertension. Journal of Human Hypertension, 2013, 27, 663-670.	1.0	77
125	Antihypertensive Treatment and Renal Protection: the role of drugs inhibiting the renin-angiotensin-aldosterone system. High Blood Pressure and Cardiovascular Prevention, 2013, 20, 273-282.	1.0	9
126	Global Cardiovascular Risk Assessment in the Management of Primary Hypertension: The Role of the Kidney. International Journal of Hypertension, 2013, 2013, 1-4.	0.5	4

#	Article	IF	CITATIONS
127	Subclinical functional and structural renal abnormalities predict new onset type 2 diabetes in patients with primary hypertension. Journal of Human Hypertension, 2013, 27, 95-99.	1.0	11
128	Serum Uric Acid and Blood Pressure in Children at Cardiovascular Risk. Pediatrics, 2013, 132, e93-e99.	1.0	88
129	The liver and the kidney: two critical organs influencing the atherothrombotic risk in metabolic syndrome. Thrombosis and Haemostasis, 2013, 110, 940-958.	1.8	20
130	Uric acid: bystander or active player in the development of cardiovascular and renal damage. Giornale De Techniche Nefrologiche & Dialitiche, 2013, 25, 20-25.	0.1	0
131	RAAS Inhibition and Renal Protection. Current Pharmaceutical Design, 2012, 18, 971-980.	0.9	17
132	Metabolic syndrome and chronic kidney disease in high-risk Italian hypertensive patients: the I-DEMAND study. Journal of Nephrology, 2012, 25, 63-74.	0.9	15
133	Chronic Kidney Disease in the Hypertensive Patient. High Blood Pressure and Cardiovascular Prevention, 2011, 18, 31-36.	1.0	6
134	Combined use of urinary neutrophil gelatinase-associated lipocalin (uNGAL) and albumin as markers of early cardiac damage in primary hypertension. Clinica Chimica Acta, 2011, 412, 1951-1956.	0.5	10
135	Serum Uric Acid Levels Predict New-Onset Type 2 Diabetes in Hospitalized Patients With Primary Hypertension: The MAGIC Study. Diabetes Care, 2011, 34, 126-128.	4.3	65
136	Chronic kidney disease in hypertension under specialist care: the I-DEMAND study. Journal of Hypertension, 2010, 28, 156-162.	0.3	40
137	Combined effect of albuminuria and estimated glomerular filtration rate on cardiovascular events and all-cause mortality in uncomplicated hypertensive patients. Journal of Hypertension, 2010, 28, 848-855.	0.3	30
138	Chronic Kidney Disease and Albuminuria in Arterial Hypertension. Current Hypertension Reports, 2010, 12, 335-341.	1.5	13
139	Microalbuminuria Is a Predictor of Chronic Renal Insufficiency in Patients without Diabetes and with Hypertension. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1099-1106.	2.2	50
140	Overall health assessment: a renal perspective. Lancet, The, 2010, 375, 2053-2054.	6.3	16
141	Coronary Flow Reserve Is Impaired in Hypertensive Patients With Subclinical Renal Damage. American Journal of Hypertension, 2009, 22, 191-196.	1.0	32
142	Renal and cardiac abnormalities in primary hypertension. Journal of Hypertension, 2009, 27, 1064-1073.	0.3	22
143	Vascular Permeability, Blood Pressure, and Organ Damage in Primary Hypertension. Hypertension Research, 2008, 31, 873-879.	1.5	11
144	Global risk stratification in primary hypertension: the role of the kidney. Journal of Hypertension, 2008, 26, 427-432.	0.3	28

#	Article	IF	CITATIONS
145	Inappropriate left ventricular mass is associated with microalbuminuria independently of left ventricular hypertrophy in primary hypertension. Journal of Hypertension, 2008, 26, 345-350.	0.3	13
146	Metabolic syndrome and ambulatory arterial stiffness index in non-diabetic patients with primary hypertension. Journal of Human Hypertension, 2007, 21, 802-807.	1.0	20
147	Cardionephrology, an emerging discipline: highlights of the Sixth Genoa Meeting on Hypertension, Diabetes and Renal Disease. Therapy: Open Access in Clinical Medicine, 2007, 4, 487-489.	0.2	Ο
148	C-reactive protein and target organ damage in untreated patients with primary hypertension. Journal of the American Society of Hypertension, 2007, 1, 407-413.	2.3	8
149	Mild Hyperuricemia and Subclinical Renal Damage in Untreated Primary Hypertension. American Journal of Hypertension, 2007, 20, 1276-1282.	1.0	46
150	Microalbuminuria and Cardiovascular Risk Assessment in Primary Hypertension: Should Threshold Levels Be Revised?. American Journal of Hypertension, 2006, 19, 728-734.	1.0	15
151	Microalbuminuria, Blood Pressure Load, and Systemic Vascular Permeability in Primary Hypertension. American Journal of Hypertension, 2006, 19, 1183-1189.	1.0	25
152	Serum Uric Acid as a Risk Factor for Cardiovascular and Renal Disease: An Old Controversy Revived. Journal of Clinical Hypertension, 2006, 8, 510-518.	1.0	40
153	Predicting cardiovascular risk using creatinine clearance and an artificial neural network in primary hypertension. Journal of Hypertension, 2006, 24, 1281-1286.	0.3	4
154	Ambulatory arterial stiffness index and renal abnormalities in primary hypertension. Journal of Hypertension, 2006, 24, 2033-2038.	0.3	77
155	Evaluation of Subclinical Organ Damage for Risk Assessment and Treatment in the Hypertensive Patient: Role of Microalbuminuria. Journal of the American Society of Nephrology: JASN, 2006, 17, S112-S114.	3.0	19
156	Microalbuminuria In Primary Hypertension. Current Hypertension Reviews, 2006, 2, 11-19.	0.5	2
157	Metabolic Syndrome and Cardiovascular Risk in Primary Hypertension. Journal of the American Society of Nephrology: JASN, 2006, 17, S120-S122.	3.0	20
158	Increased Ambulatory Arterial Stiffness Index Is Associated With Target Organ Damage in Primary Hypertension. Hypertension, 2006, 48, 397-403.	1.3	135
159	Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients. Journal of Internal Medicine, 2005, 257, 454-460.	2.7	117
160	Impact of Target Organ Damage Assessment in the Evaluation of Global Risk in Patients with Essential Hypertension: Figure 1 Journal of the American Society of Nephrology: JASN, 2005, 16, S89-S91.	3.0	16
161	Serum Uric Acid and Target Organ Damage in Primary Hypertension. Hypertension, 2005, 45, 991-996.	1.3	145
162	Role of Microalbuminuria in the Assessment of Cardiovascular Risk in Essential Hypertension. Journal of the American Society of Nephrology: JASN, 2005, 16, S39-S41.	3.0	19

#	Article	IF	CITATIONS
163	Mild Renal Dysfunction and Renal Vascular Resistance in Primary Hypertension. American Journal of Hypertension, 2005, 18, 966-971.	1.0	56
164	Creatinine clearance and signs of end-organ damage in primary hypertension. Journal of Human Hypertension, 2004, 18, 511-516.	1.0	19
165	Optimizing global risk evaluation in primary hypertension. Journal of Hypertension, 2004, 22, 907-913.	0.3	36
166	Mild Renal Dysfunction and Subclinical Cardiovascular Damage in Primary Hypertension. Hypertension, 2003, 42, 14-18.	1.3	69
167	Microalbuminuria, Cardiovascular, and Renal Risk in Primary Hypertension. Journal of the American Society of Nephrology: JASN, 2002, 13, S169-S172.	3.0	62
168	Pulse pressure and subclinical cardiovascular damage in primary hypertension. Nephrology Dialysis Transplantation, 2002, 17, 1779-1785.	0.4	27
169	Microalbuminuria is an integrated marker of subclinical organ damage in primary hypertension. Journal of Human Hypertension, 2002, 16, 399-404.	1.0	60
170	Microalbuminuria identifies overall cardiovascular risk in essential hypertension: an artificial neural network-based approach Journal of Hypertension, 2002, 20, 1315-1321.	0.3	61
171	Changes in Renal Resistive Index and Urinary Albumin Excretion in Hypertensive Patients under Long-Term Treatment with Lisinopril or Nifedipine GITS. Nephron, 2002, 90, 169-173.	0.9	63
172	Microalbuminuria and subclinical cerebrovascular damage in essential hypertension. Journal of Nephrology, 2002, 15, 519-24.	0.9	34
173	5,10-methylenetetrahydrofolate reductase polymorphism and early organ damage in primary hypertension. American Journal of Hypertension, 2001, 14, 371-376.	1.0	27
174	Pulse pressure (PP) and early signs of target organ damage (TOD) in essential hypertension (EH). American Journal of Hypertension, 2001, 14, A161.	1.0	0
175	Genetic polymorphism of the renin-angiotensin system and organ damage in essential hypertension. Kidney International, 2000, 57, 561-569.	2.6	62
176	Left ventricular geometry and function in patients with essential hypertension and microalbuminuria. Journal of Hypertension, 1999, 17, 993-1000.	0.3	97
177	Microalbuminuria Is an Early Marker of Target Organ Damage in Essential Hypertension. American Journal of Hypertension, 1998, 11, 430-438.	1.0	76
178	Prevalence and Clinical Correlates of Microalbuminuria in Essential Hypertension. Hypertension, 1997, 30, 1135-1143.	1.3	165
179	The role of uric acid in renal damage - A history of inflammatory pathways and vascular remodeling. , 0, , .		2